Browse: Companies | People | Financial Organizations
Home > Financial Organizations > Altitude Life Science Ventures

General Information

Websitealtitudefunds.com
Phone(206) 999-3348
Email
Employees

Funds

Offices

Seattle, USA
701 Fifth Avenue
Suite 6300
Seattle, WA, 98104
USA

People

Tags

Altitude Life Science Ventures

Philosophy is to focus on life science markets with strong demand and growth potential, and then back the highest-quality entrepreneurs in those markets to build defensible, strong, and long-term businesses.

build portfolio among attractive life science sectors in a manner that balances risk while maximizing potential synergies and ultimate returns. Our focus is on opportunities in biotechnology, medical devices, and diagnostics, but we are continually responsive to the best areas for investing in order to adapt to changing market conditions.

Invest in companies that:

* are pursuing substantial and growing market opportunities
* possess a unique and proprietary technology, with a clear competitive advantage
* are early-stage opportunities
* have or will attract strong management
* have a strong investment syndicate
* offer a defined path to liquidity

Milestones

Investments

Company Date Round Size Participants
Cambrios Technologies 11/09Series D$14.5M14
Constellation Pharmaceuticals 8/09Unattributed$17.2M4
Limerick BioPharma 7/09Series C$15M3
Limerick BioPharma 6/08Unattributed$15.2M3
Kythera Biopharmaceuticals 5/08Series C$30M9

Videos

Sources

  1. Cambrios lands $14.5M for electronic display components (deals.venturebeat.com) [edit]
  2. Constellation Pharmaceuticals, Inc. Closes $17 Million in Funding (constellationpharma.com) [edit]
  3. Limerick lands $15M in Series C (fiercebiotech.com) [edit]
  4. Limerick BioPharma raises $15.2M for drug bioavailability (deals.venturebeat.com) [edit]
  5. Capital Funding Report [edit]
Edit This Page
Last Edited 11/9/09

Revision History RSS Picture

External Links

Embed Widget

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy